• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Nov 26;16(1):10566.
doi: 10.1038/s41467-025-65596-0. Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution

Minxiang Xie[SUP] #[/SUP][SUP] 1 [/SUP], Yinong Qiu[SUP] #[/SUP][SUP] 1 [/SUP], Xiaoyu Zhao[SUP] #[/SUP][SUP] 2 3 [/SUP], Jialu Shi[SUP] #[/SUP][SUP] 4 [/SUP], Yuanchen Liu[SUP] #[/SUP][SUP] 4 [/SUP], Qingsong Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Jiaying He[SUP] #[/SUP][SUP] 5 [/SUP], Jiayan Li[SUP] #[/SUP][SUP] 3 [/SUP], Luotian Liu[SUP] 1 [/SUP], Siyuan Sun[SUP] 1 [/SUP], Yuzhen Zhu[SUP] 6 [/SUP], Qiyu Mao[SUP] 1 [/SUP], Yiming Long[SUP] 1 [/SUP], Thiago Y Oliveira[SUP] 7 [/SUP], Zijun Wang[SUP] 7 [/SUP], Yunjiao Zhou[SUP] 8 [/SUP], Yan Yan[SUP] 1 [/SUP], Anqi Xia[SUP] 1 [/SUP], Wenjing Zai[SUP] 1 [/SUP], Christian T Mayer[SUP] 9 [/SUP], Youhua Xie[SUP] 1 [/SUP], Shibo Jiang[SUP] 1 [/SUP], Lu Lu[SUP] 1 [/SUP], Rong Xia[SUP] 10 [/SUP], Fan Wu[SUP] 11 [/SUP], Lei Sun[SUP] 12 [/SUP], Pengfei Wang[SUP] 13 [/SUP], Hin Chu[SUP] 14 [/SUP], Qiao Wang[SUP] 15 [/SUP]



Affiliations
Abstract

The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein continues to evolve, facilitating antibody evasion. It remains unclear whether any conserved RBD epitopes persist across SARS-CoV-2 variants and whether vaccination and/or breakthrough infection (BTI) can elicit antibodies capable of targeting these conserved regions to counter future variants. Here, using a heterogeneous double-bait single B-cell sorting strategy, we identify a subset of antibodies with broad-spectrum RBD binding, including recognition of SARS-CoV-1 and emerging variants such as EG.5.1, BA.2.86, JN.1, and KP.2/3. These broadly binding antibodies (bbAbs) exhibit elevated levels of somatic hypermutation but are infrequently derived from clonally expanded B lymphocytes. Passive transfer of representative bbAbs reduces viral infection in a male hamster model. Structural analyses reveals that these bbAbs primarily target three distinct, highly conserved RBD epitopes, suggesting potential regions of future mutational pressure and highlighting the presence of conserved and immunogenic RBD conformations that may serve as a foundation for the development of broadly protective vaccines.


 
Back
Top Bottom